Prelude Therapeutics Incorporated
NASDAQ:PRLD
1.25 (USD) • At close September 8, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | Prelude Therapeutics Incorporated | 
| Symbool | PRLD | 
| Munteenheid | USD | 
| Prijs | 1.25 | 
| Beurswaarde    |  68,980,434 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 0.61 - 5.53 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Dr. Krishna Vaddi D.V.M., Ph.D. | 
| Website | https://www.preludetx.com | 
An error occurred while fetching data.
Over Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









